

SUBMIT ONLY REQUESTED DOCUMENTS


Required field (*) M-US-00006694(v6.0)

Services Requested (Check all that apply)
 Benefits Investigation/Prior Authorization
 Refer Patient to Co-pay Assistance
 Appeals Support

Step 1 Patient Information

*First name: _____ *Last name: _____
 *Date of birth (MM/DD/YYYY): ____ / ____ / ____ Gender: Male Female
 Street: _____ Apt: _____
 City: _____ *State: _____ ZIP: _____
 Home phone: (____) ____ - _____ Cell phone: (____) ____ - _____ Do not contact patient
 Preferred language: English Spanish Other: _____ Has patient started therapy? Yes No
 Alternate contact name: _____ Relationship: _____ Alt. phone: (____) ____ - _____

Step 2 Insurance Information

Is the patient insured? Yes No
 
If patient is uninsured, please complete the Genentech Patient Foundation Enrollment Form or call (888) 941-3331 for assistance.
If insured, please fill out the information below or attach a copy of the patient's insurance cards.

	Primary Insurance	Secondary Insurance
Insurance name		
Subscriber name (if not patient)		
Subscriber/Policy ID #		
Group #		
Insurance phone		

Step 3 Patient's Therapy (Check all that apply)

VABYSMO® (faricimab-svoa)
 SUSVIMO™ (ranibizumab injection)
 LUCENTIS® (ranibizumab injection)

Initial Fill and Implant Procedure Refill-Exchange Procedure

Step 4 Diagnosis and Clinical Information

Please provide the appropriate diagnosis code(s) to the highest level of specificity. For coding information, please visit Genentech-Access.com/Ophthalmology.

Anticipated date of treatment: ____ / ____ / ____ *Diagnosis code(s): _____

SUBMIT ONLY REQUESTED DOCUMENTS

Required field (*) M-US-00006694(v6.0)

Step 5 Patient Information

*First name: _____ *Last name: _____ *Date of birth (MM/DD/YYYY): ____ / ____ / ____

Step 6 Prescriber Information

*First name: _____ *Last name: _____

*Practice name: _____

*Street: _____ Suite: _____ *City: _____

*State: _____ *ZIP: _____ Prescriber tax ID #: _____

Prescriber NPI[†] #: _____ Group NPI[†] #: _____

Office contact: _____ Contact phone: (____) ____ - ____ Contact fax: (____) ____ - ____

If you are a resident of a US state that provides certain rights with respect to your personal information, a complete description of the personal information we may collect and process, the purposes for which it is used by Genentech, and your rights under your state's privacy laws concerning your personal information can be found in our privacy notice at <https://www.gene.com/privacy-policy>.

Step 7 Administration Information (Complete for SUSVIMO™ Only)

Ambulatory Surgical Center Hospital Outpatient Department In Office

Place of administration name: _____ Tax ID #: _____

Street: _____ Suite: _____ City: _____

State: _____ ZIP: _____ NPI[†] #: _____

Step 8 Genentech Ophthalmology Co-pay Program Enrollment for Patients With Commercial Insurance

By checking this box, you certify that: You have the patient's consent to enroll in the Genentech Ophthalmology Co-pay Program for assistance with drug out-of-pocket costs and/or Genentech Ophthalmology administration out-of-pocket costs. The patient is not using and you will not bill any federal or state-funded health care program. This includes, but is not limited to, Medicare, Medicaid, Medigap, VA, DoD and TRICARE. The patient is not currently receiving Genentech Ophthalmology treatment from the Genentech Patient Foundation. The patient is not currently receiving assistance from any other charitable organization for any of their out-of-pocket costs that are covered by the Genentech Ophthalmology Co-pay Program. You have read and accepted the Program Terms and Conditions as written here: [EyeOnCopay.com/TandCs](https://www.gene.com/eyeoncopay). Genentech reserves the right to rescind, revoke or amend the Programs without notice at any time.

Step 9 Health Care Provider Certification

By submitting this form, I certify: (a) The above therapy is medically necessary for this patient and the treatment decision has been made by the prescribing physician. (b) If the indication for which this Genentech product is being prescribed to treat is not listed in the FDA-approved label, the prescriber is prescribing the medication for an "unapproved" use, meaning that the FDA has not approved the efficacy, dosage amount or safety of this medication for such a use. (c) The provider's office received the authorization to release the information above and other protected health information (as defined by the Health Insurance Portability and Accountability Act of 1996 [HIPAA]) to Genentech, Inc., Genentech Access Solutions, the contracted dispensing pharmacy, or other contractors for the purpose of requesting reimbursement support, assisting in initiating or continuing therapy, as a break in treatment would negatively impact the patient's therapeutic outcome. (d) The provider's office will not attempt to seek reimbursement for free product provided to the patient. (e) The services requested on behalf of the patient may include benefits investigation (BI), prior authorization (PA) and appeals support, co-pay card and co-pay assistance foundation referral. In the absence of a checkbox selecting a service, Genentech Access Solutions will perform BI/PA services on behalf of the patient. (f) **No action on these services will be taken until the patient consent document has been received.**

[†]National Provider Identifier.

LUCENTIS®, VABYSMO® and the Access Solutions logo are registered trademarks and SUSVIMO™ is a trademark of Genentech, Inc.

©2024 Genentech USA, Inc. So. San Francisco, CA All rights reserved. Printed in USA